Literature DB >> 19844224

When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.

S-M Huang1, R Temple, S Xiao, L Zhang, L J Lesko.   

Abstract

To optimize drug therapy for individuals, it is critical to understand how various intrinsic (e.g., age, gender, race, genetics, organ impairment) and extrinsic factors (e.g., diet, smoking, concomitantly administered drugs) affect drug exposure and response.(1) Up to now, it has been far easier to discover effects on exposure caused by these factors, and the US Food and Drug Administration (FDA) has published several guidance documents with recommendations on how to evaluate these factors during drug development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19844224     DOI: 10.1038/clpt.2009.190

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  28 in total

1.  Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment.

Authors:  Richard A Preston; Grigor Mamikonyan; Stephane DeGraff; James Chiou; Christopher J Kemper; Allan Xu; Mushtaque Mastim; Ravindra Yeole; Rajesh Chavan; Anasuya Patel; H David Friedland; Ashima Bhatia
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

2.  Potentially inappropriate prescribing of renally cleared drugs in elderly patients in community and aged care settings.

Authors:  Aarati Khanal; Gregory M Peterson; Ronald L Castelino; Matthew D Jose
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

Review 3.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

4.  Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model.

Authors:  Jia Li; Hai-Fang Guo; Can Liu; Zeyu Zhong; Li Liu; Xiao-Dong Liu
Journal:  Clin Pharmacokinet       Date:  2015-02       Impact factor: 6.447

5.  Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies.

Authors:  Jan H Beumer; Fei Ding; Hussein Tawbi; Yan Lin; Diana Viluh; Indrani Chatterjee; Matthew Rinker; Selina L Chow; S Percy Ivy
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

6.  Potentially inappropriate prescribing of primarily renally cleared medications for older veterans affairs nursing home patients.

Authors:  Joseph T Hanlon; Xiaoqiang Wang; Steven M Handler; Steven Weisbord; Mary Jo Pugh; Todd Semla; Roslyn A Stone; Sherrie L Aspinall
Journal:  J Am Med Dir Assoc       Date:  2010-10-02       Impact factor: 4.669

Review 7.  Methods of Estimating Kidney Function for Drug Dosing in Special Populations.

Authors:  Laura A Hart; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

8.  Influence of kidney function on risk of hemorrhage among patients taking warfarin: a cohort study.

Authors:  Mohit A Limdi; Michael R Crowley; T Mark Beasley; Nita A Limdi; Michael Allon
Journal:  Am J Kidney Dis       Date:  2012-11-16       Impact factor: 8.860

Review 9.  Clinical pharmacology of axitinib.

Authors:  Ying Chen; Michael A Tortorici; May Garrett; Brian Hee; Karen J Klamerus; Yazdi K Pithavala
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

10.  Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.

Authors:  Ying Chen; Brian I Rini; Robert J Motzer; Janice P Dutcher; Olivier Rixe; George Wilding; Walter M Stadler; Jamal Tarazi; May Garrett; Yazdi K Pithavala
Journal:  Target Oncol       Date:  2016-04       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.